Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Artivion, Inc. (AORT) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Artivion, Inc.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 784199.
Total stock buying since 2015: $883,118.
Total stock sales since 2015: $45,829,033.
Total stock option exercises since 2015: $13,932,803.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 2,100 | $53,106 | 355,354 | $10,738,384 | 174,586 | $3,660,432 |
| 2024 | 0 | $0 | 234,400 | $4,971,272 | 85,217 | $1,454,293 |
| 2023 | 0 | $0 | 204,772 | $2,858,155 | 146,226 | $1,584,598 |
| 2022 | 0 | $0 | 58,702 | $1,088,574 | 42,553 | $468,083 |
| 2021 | 15,600 | $270,797 | 160,366 | $4,530,470 | 119,275 | $1,451,697 |
| 2020 | 20,000 | $332,730 | 56,285 | $1,335,284 | 48,651 | $482,194 |
| 2019 | 5,000 | $117,355 | 128,222 | $3,889,005 | 54,986 | $420,534 |
| 2018 | 0 | $0 | 339,333 | $10,498,114 | 256,143 | $2,381,974 |
| 2017 | 0 | $0 | 237,993 | $4,890,608 | 118,667 | $655,474 |
| 2016 | 10,000 | $109,130 | 43,000 | $474,600 | 85,033 | $526,144 |
| 2015 | 0 | $0 | 51,698 | $554,567 | 95,550 | $847,380 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-03-01 | Horton Amy (VP, Chief Accounting Officer) | Sale | 13,619 | 25.53 | 347,706 |
| 2021-02-17 | Maier Dennis B (Vice President, Operations) | Sale | 7,197 | 24.69 | 177,686 |
| 2021-02-17 | Maier Dennis B (Vice President, Operations) | Option Ex | 6,630 | 21.55 | 142,876 |
| 2020-12-15 | Capps Scott B (VP, Clinical Research) | Sale | 8,366 | 21.34 | 178,555 |
| 2020-12-15 | Capps Scott B (VP, Clinical Research) | Option Ex | 10,000 | 9.97 | 99,700 |
| 2020-12-14 | Maier Dennis B (Vice President, Operations) | Sale | 1,843 | 21.85 | 40,269 |
| 2020-12-14 | Horton Amy (VP, Chief Accounting Officer) | Option Ex | 6,666 | 9.97 | 66,460 |
| 2020-12-14 | Mccall Ronald D (Director) | Sale | 4,638 | 21.79 | 101,066 |
| 2020-12-10 | Lee David Ashley (Executive VP, COO & CFO) | Sale | 16,666 | 23.00 | 383,318 |
| 2020-12-10 | Lee David Ashley (Executive VP, COO & CFO) | Option Ex | 16,666 | 9.97 | 166,160 |
| 2020-12-01 | Horton Amy (VP, Chief Accounting Officer) | Sale | 6,666 | 20.78 | 138,506 |
| 2020-12-01 | Horton Amy (VP, Chief Accounting Officer) | Option Ex | 6,666 | 9.97 | 66,460 |
| 2020-09-16 | Davis John E (Senior VP, Global Sales) | Buy | 10,000 | 16.65 | 166,460 |
| 2020-09-16 | Bullock James (Director) | Buy | 10,000 | 16.63 | 166,270 |
| 2020-05-28 | Horton Amy (VP, Chief Accounting Officer) | Sale | 3,000 | 23.80 | 71,415 |
| 2020-05-05 | Mccall Ronald D (Director) | Sale | 1,719 | 22.82 | 39,218 |
| 2020-02-24 | Mccall Ronald D (Director) | Sale | 4,734 | 26.05 | 123,339 |
| 2020-01-21 | Holloway Jean F (VP, General Counsel) | Sale | 8,458 | 30.00 | 253,748 |
| 2020-01-21 | Holloway Jean F (VP, General Counsel) | Option Ex | 8,458 | 9.64 | 81,535 |
| 2020-01-16 | Holloway Jean F (VP, General Counsel) | Sale | 195 | 30.00 | 5,850 |
| 2020-01-16 | Holloway Jean F (VP, General Counsel) | Option Ex | 195 | 9.64 | 1,879 |
| 2019-12-12 | Holloway Jean F (VP, General Counsel) | Sale | 3,000 | 26.00 | 78,000 |
| 2019-12-12 | Holloway Jean F (VP, General Counsel) | Option Ex | 3,000 | 10.24 | 30,720 |
| 2019-11-26 | Capps Scott B (VP, Clinical Research) | Sale | 7,184 | 24.93 | 179,111 |
| 2019-11-26 | Capps Scott B (VP, Clinical Research) | Option Ex | 10,000 | 6.12 | 61,200 |
| 2019-11-19 | Mccall Ronald D (Director) | Sale | 4,000 | 24.64 | 98,564 |
| 2019-11-13 | Mackin James P (President & CEO) | Buy | 5,000 | 23.47 | 117,355 |
| 2019-05-31 | Capps Scott B (VP, Clinical Research) | Sale | 2,000 | 28.55 | 57,100 |
| 2019-05-24 | Mccall Ronald D (Director) | Sale | 1,563 | 28.47 | 44,498 |
| 2019-05-23 | Mccall Ronald D (Director) | Sale | 1,000 | 28.00 | 28,000 |
| 2019-05-22 | Mccall Ronald D (Director) | Sale | 2,700 | 29.02 | 78,345 |
| 2019-05-06 | Holloway Jean F (VP, General Counsel) | Sale | 8,654 | 32.00 | 276,928 |
| 2019-05-06 | Holloway Jean F (VP, General Counsel) | Option Ex | 8,654 | 9.64 | 83,424 |
| 2019-05-03 | Mackin James P (President & CEO) | Sale | 50,000 | 31.31 | 1,565,700 |
| 2019-05-03 | Lee David Ashley (Executive VP, COO & CFO) | Sale | 25,255 | 31.36 | 792,072 |
| 2019-05-03 | Lee David Ashley (Executive VP, COO & CFO) | Option Ex | 16,666 | 6.12 | 101,995 |
| 2019-05-01 | Holloway Jean F (VP, General Counsel) | Sale | 10,000 | 31.50 | 315,000 |
| 2019-05-01 | Holloway Jean F (VP, General Counsel) | Option Ex | 10,000 | 10.24 | 102,400 |
| 2019-03-06 | Horton Amy (VP, Chief Accounting Officer) | Sale | 6,666 | 29.15 | 194,300 |
| 2019-03-06 | Horton Amy (VP, Chief Accounting Officer) | Option Ex | 6,666 | 6.12 | 40,795 |
| 2019-02-21 | Mccall Ronald D (Director) | Sale | 6,200 | 29.26 | 181,387 |
| 2018-09-18 | Davis John E (Senior VP, Global Sales) | Sale | 3,333 | 33.86 | 112,842 |
| 2018-09-18 | Davis John E (Senior VP, Global Sales) | Option Ex | 3,333 | 9.64 | 32,130 |
| 2018-09-05 | Ronald C Elkins (Director) | Sale | 5,000 | 34.53 | 172,670 |
| 2018-08-30 | Capps Scott B (VP, Clinical Research) | Sale | 6,332 | 34.10 | 215,921 |
| 2018-08-30 | Capps Scott B (VP, Clinical Research) | Option Ex | 8,332 | 5.67 | 47,242 |
| 2018-08-15 | Mackin James P (President & CEO) | Sale | 9,851 | 31.80 | 313,212 |
| 2018-08-15 | Mackin James P (President & CEO) | Option Ex | 9,851 | 10.24 | 100,874 |
| 2018-08-15 | Lee David Ashley (Executive VP, COO & CFO) | Sale | 16,666 | 31.92 | 531,995 |
| 2018-08-15 | Lee David Ashley (Executive VP, COO & CFO) | Option Ex | 16,666 | 5.67 | 94,496 |
| 2018-08-14 | Mackin James P (President & CEO) | Sale | 37,077 | 32.22 | 1,194,472 |
| 2018-08-14 | Mackin James P (President & CEO) | Option Ex | 37,077 | 10.24 | 379,668 |
| 2018-08-14 | Morgan Harvey (Director) | Sale | 4,812 | 32.66 | 157,150 |
| 2018-08-13 | Mackin James P (President & CEO) | Sale | 103,072 | 32.17 | 3,315,929 |
| 2018-08-13 | Mackin James P (President & CEO) | Option Ex | 103,072 | 10.24 | 1,055,457 |
| 2018-08-13 | Morgan Harvey (Director) | Sale | 5,188 | 32.44 | 168,283 |
| 2018-08-10 | Holloway Jean F (VP, General Counsel) | Sale | 1,500 | 33.50 | 50,250 |
| 2018-08-10 | Holloway Jean F (VP, General Counsel) | Option Ex | 1,500 | 10.28 | 15,419 |
| 2018-08-10 | Mackin James P (President & CEO) | Sale | 42,675 | 33.35 | 1,423,381 |
| 2018-08-10 | Horton Amy (VP, Chief Accounting Officer) | Sale | 3,000 | 32.85 | 98,550 |
| 2018-08-10 | Lee David Ashley (Executive VP, COO & CFO) | Sale | 10,247 | 32.98 | 337,925 |
| 2018-08-10 | Ronald C Elkins (Director) | Sale | 1,154 | 33.27 | 38,393 |
| 2018-08-09 | Mccall Ronald D (Director) | Sale | 2,750 | 32.69 | 89,900 |
| 2018-08-07 | Holloway Jean F (VP, General Counsel) | Sale | 4,000 | 32.50 | 130,000 |
| 2018-08-07 | Holloway Jean F (VP, General Counsel) | Option Ex | 4,000 | 10.28 | 41,120 |
| 2018-07-26 | Davis John E (Senior VP, Global Sales) | Sale | 3,391 | 31.00 | 105,121 |
| 2018-07-26 | Davis John E (Senior VP, Global Sales) | Option Ex | 3,391 | 16.30 | 55,273 |
| 2018-07-23 | Holloway Jean F (VP, General Counsel) | Sale | 1,500 | 30.50 | 45,750 |
| 2018-07-23 | Holloway Jean F (VP, General Counsel) | Option Ex | 1,500 | 10.28 | 15,419 |
| 2018-07-06 | Davis John E (Senior VP, Global Sales) | Sale | 3,391 | 30.00 | 101,730 |
| 2018-07-06 | Davis John E (Senior VP, Global Sales) | Option Ex | 3,391 | 16.30 | 55,273 |
| 2018-06-14 | Davis John E (Senior VP, Global Sales) | Option Ex | 4,372 | 10.24 | 44,769 |
| 2018-06-14 | Ronald C Elkins (Director) | Sale | 5,000 | 28.89 | 144,445 |
| 2018-06-01 | Davis John E (Senior VP, Global Sales) | Sale | 4,373 | 28.00 | 122,444 |
| 2018-06-01 | Davis John E (Senior VP, Global Sales) | Option Ex | 4,373 | 10.24 | 44,779 |
| 2018-06-01 | Horton Amy (VP, Chief Accounting Officer) | Sale | 2,256 | 28.00 | 63,168 |
| 2018-06-01 | Horton Amy (VP, Chief Accounting Officer) | Option Ex | 5,000 | 5.67 | 28,350 |
| 2018-05-30 | Ronald C Elkins (Director) | Sale | 3,000 | 27.18 | 81,525 |
| 2018-05-16 | Davis John E (Senior VP, Global Sales) | Sale | 4,373 | 27.00 | 118,071 |
| 2018-05-16 | Davis John E (Senior VP, Global Sales) | Option Ex | 4,373 | 10.24 | 44,779 |
| 2018-05-14 | Ronald C Elkins (Director) | Sale | 10,000 | 24.75 | 247,500 |
| 2018-05-10 | Mccall Ronald D (Director) | Sale | 2,000 | 25.39 | 50,782 |
| 2018-05-10 | Ronald C Elkins (Director) | Sale | 5,000 | 25.30 | 126,500 |
| 2018-05-09 | Horton Amy (VP, Chief Accounting Officer) | Sale | 4,000 | 25.94 | 103,764 |
| 2018-05-09 | Lee David Ashley (Executive VP, COO & CFO) | Sale | 10,000 | 25.70 | 257,000 |
| 2018-05-09 | Mccall Ronald D (Director) | Sale | 2,240 | 25.67 | 57,494 |
| 2018-05-08 | Davis John E (Senior VP, Global Sales) | Sale | 4,373 | 26.00 | 113,698 |
| 2018-05-08 | Davis John E (Senior VP, Global Sales) | Option Ex | 4,373 | 10.24 | 44,779 |
| 2018-05-08 | Mccall Ronald D (Director) | Sale | 260 | 25.95 | 6,747 |
| 2018-05-08 | Ronald C Elkins (Director) | Sale | 1,852 | 25.58 | 47,377 |
| 2018-05-03 | Davis John E (Senior VP, Global Sales) | Sale | 3,334 | 24.00 | 80,016 |
| 2018-05-03 | Davis John E (Senior VP, Global Sales) | Option Ex | 3,334 | 9.64 | 32,139 |
| 2018-05-03 | Ronald C Elkins (Director) | Sale | 2,000 | 24.00 | 48,000 |
| 2018-04-17 | Davis John E (Senior VP, Global Sales) | Sale | 3,333 | 23.00 | 76,659 |
| 2018-04-17 | Davis John E (Senior VP, Global Sales) | Option Ex | 3,333 | 9.64 | 32,130 |
| 2018-03-08 | Mccall Ronald D (Director) | Sale | 5,000 | 21.09 | 105,450 |
| 2018-03-08 | Ronald C Elkins (Director) | Sale | 2,000 | 22.00 | 44,000 |
| 2018-02-13 | Capps Scott B (VP, Clinical Research) | Option Ex | 31,333 | 5.12 | 160,424 |
| 2018-01-01 | Mcdermid James M (SVP, CHRO) | Option Ex | 1,179 | 16.23 | 19,141 |
| 2018-01-01 | Saurini Sherry M (VP, Quality) | Option Ex | 191 | 16.23 | 3,100 |
| 2018-01-01 | Davis John E (Senior VP, Global Sales) | Option Ex | 1,308 | 16.23 | 21,235 |
| 2018-01-01 | Holloway Jean F (VP, General Counsel) | Option Ex | 861 | 16.23 | 13,978 |
| 2017-12-15 | Ronald C Elkins (Director) | Sale | 1,000 | 20.00 | 20,000 |
| 2017-11-16 | Gale David C (VP, Research & Development) | Sale | 20,000 | 19.62 | 392,500 |
| 2017-11-16 | Gale David C (VP, Research & Development) | Option Ex | 20,000 | 5.94 | 118,800 |
| 2017-11-09 | Lee David Ashley (Executive VP, COO & CFO) | Sale | 30,143 | 18.57 | 559,876 |
| 2017-11-09 | Lee David Ashley (Executive VP, COO & CFO) | Option Ex | 30,143 | 5.12 | 154,332 |
| 2017-11-08 | Horton Amy (VP, Chief Accounting Officer) | Sale | 4,000 | 19.00 | 76,000 |
| 2017-11-08 | Lee David Ashley (Executive VP, COO & CFO) | Sale | 33,190 | 19.00 | 630,543 |
| 2017-11-08 | Lee David Ashley (Executive VP, COO & CFO) | Option Ex | 33,190 | 5.12 | 169,932 |
| 2017-11-06 | Ronald C Elkins (Director) | Sale | 1,000 | 19.03 | 19,030 |
| 2017-10-02 | Benson James (Director) | Sale | 2,000 | 22.80 | 45,600 |
| 2017-09-06 | Mackin James P (President & CEO) | Sale | 81,950 | 21.97 | 1,800,687 |
| 2017-09-05 | Mackin James P (President & CEO) | Sale | 43,050 | 22.09 | 951,060 |
| 2017-09-05 | Ronald C Elkins (Director) | Sale | 1,000 | 22.00 | 22,000 |
| 2017-06-27 | Horton Amy (VP, Chief Accounting Officer) | Sale | 9,577 | 20.00 | 191,540 |
| 2017-06-27 | Horton Amy (VP, Chief Accounting Officer) | Option Ex | 18,667 | 5.12 | 95,575 |
| 2017-02-22 | Capps Scott B (VP, Clinical Research) | Sale | 11,083 | 16.40 | 181,772 |
| 2017-02-22 | Capps Scott B (VP, Clinical Research) | Option Ex | 16,667 | 7.01 | 116,835 |
| 2016-09-12 | Holloway Jean F (VP, General Counsel) | Option Ex | 3,000 | 9.64 | 28,920 |
| 2016-09-12 | Gale David C (VP, Research & Development) | Option Ex | 3,000 | 7.01 | 21,030 |
| 2016-09-12 | Lee David Ashley (Executive VP, COO & CFO) | Option Ex | 4,486 | 7.01 | 31,446 |
| 2016-09-09 | Lee David Ashley (Executive VP, COO & CFO) | Option Ex | 28,847 | 7.01 | 202,217 |
| 2016-07-26 | Horton Amy (VP, Chief Accounting Officer) | Option Ex | 10,000 | 7.01 | 70,100 |
| 2016-07-26 | Ronald C Elkins (Director) | Sale | 2,000 | 14.00 | 28,000 |
| 2016-06-01 | Mccall Ronald D (Director) | Sale | 10,000 | 11.56 | 115,600 |
| 2016-05-10 | Benson James (Director) | Sale | 5,000 | 12.22 | 61,100 |
| 2016-04-15 | Ronald C Elkins (Director) | Sale | 1,000 | 12.00 | 12,000 |
| 2016-03-07 | Ronald C Elkins (Director) | Sale | 2,000 | 11.18 | 22,360 |
| 2016-03-04 | Mackin James P (President & CEO) | Buy | 4,600 | 10.94 | 50,324 |
| 2016-03-03 | Mackin James P (President & CEO) | Buy | 5,400 | 10.89 | 58,806 |
| 2016-02-19 | Capps Scott B (VP, Clinical Research) | Sale | 15,000 | 10.30 | 154,500 |
| 2016-02-19 | Capps Scott B (VP, Clinical Research) | Option Ex | 15,000 | 4.83 | 72,450 |
| 2016-02-18 | Lee David Ashley (Executive VP, COO & CFO) | Sale | 8,000 | 10.13 | 81,040 |
| 2016-02-18 | Lee David Ashley (Executive VP, COO & CFO) | Option Ex | 8,000 | 4.83 | 38,640 |
| 2016-02-17 | Lee David Ashley (Executive VP, COO & CFO) | Option Ex | 12,700 | 4.83 | 61,341 |
| 2015-12-28 | Lee David Ashley (Exec. VP, COO and CFO) | Sale | 700 | 11.00 | 7,700 |
| 2015-12-28 | Lee David Ashley (Exec. VP, COO and CFO) | Option Ex | 1,000 | 4.83 | 4,830 |
| 2015-11-30 | Lee David Ashley (Executive VP, COO & CFO) | Sale | 1,219 | 11.03 | 13,439 |
| 2015-11-30 | Lee David Ashley (Executive VP, COO & CFO) | Option Ex | 5,219 | 4.83 | 25,207 |
| 2015-11-27 | Lee David Ashley (Executive VP, COO & CFO) | Sale | 10,581 | 11.03 | 116,708 |
| 2015-11-27 | Lee David Ashley (Executive VP, COO & CFO) | Option Ex | 10,581 | 4.83 | 51,106 |
| 2015-09-15 | Benson James (Director) | Sale | 5,839 | 9.65 | 56,346 |
| 2015-09-11 | Benson James (Director) | Sale | 3,359 | 9.65 | 32,414 |
| 2015-02-23 | Anderson Steven G (Executive Chairman) | Option Ex | 63,750 | 9.73 | 620,287 |
| 2015-02-19 | Anderson Steven G (Executive Chairman) | Sale | 30,000 | 10.93 | 327,960 |
| 2015-02-16 | Fronk David (VP, Regulatory Affairs) | Option Ex | 15,000 | 9.73 | 145,950 |
Insider trading activities including stock purchases, stock sales, and option exercises of AORT listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Artivion, Inc. (symbol AORT, CIK number 784199) see the Securities and Exchange Commission (SEC) website.